PMH50 A BELGIAN PILOT PROJECT TESTING THE FEASIBILITY AND ACCEPTABILITY OF SHORT MESSAGE SERVICE (SMS)TEXT MESSAGING TO PATIENTS TREATED WITH QUETIAPINE  by Lodewyck, P et al.
PMH49
SF-36 AND EQ-5D QUALITY OF LIFE INSTRUMENTS IN MAJOR
DEPRESSIVE DISORDER PATIENTS: COMPARISONS OFTWO
DIFFERENTTREATMENT OPTIONS
Ergun H1,Aydemir O2, Kesebir S3, Soygur H4,Tulunay FC5
1Ankara University Faculty of Medicine, Ankara,Turkey, 2Celal Bayar
Unversity Faculty of Medicine, Manisa,Turkey, 3Kirikkale State Hospital,
Kirikkale,Turkey, 4Ankara Onkoloji Hospital, Ankara,Turkey, 5Ankara
University Medical School, Ankara,Turkey
OBJECTIVES: To assess the correlation between the two QoL
instruments (SF-36, EQ-5D) and the scores of these instruments
to HAM-D scores in patients with major depressive disorder
(DSM-IV) during 6 week treatment period. Another aim was to
compare the efﬁcacy and safety of citalopram with S-citalopram
treatments in major depressive disorder. METHODS: Seventy-
four patients older than 18 years were recruited and randomly
assigned to receive citalopram (37) or S-citalopram (37) at 3
psychiatry units. Socio-demographic characteristics of the
patients and the HAM-D, SF-36 and EQ-5D scales were collected
before and at 2, 4, and 6 weeks after the treatment. At the end of
the study patient and physicians were asked to evaluate the
treatments with verbal score. RESULTS: All patients completed
the 6 week observation period. There was not any signiﬁcant
difference between both treatments for all measured parameters
at any time point. The mean HAM-D and EQ-5D utility score for
all patients at baseline were 23.5 (0.77) and 0.44 (0.035) and
improved to 5.0 (0.51) and 0.91 (0.015) at the end of the trial
(6. week), respectively. HAM-D were found to be well correlated
with EQ-5D (r = 0.77) and with the mental health measures of
SF-36; vitality (VT) (r = 0.79), social functioning (SF) (r = 0.70),
role emotional (RE) (r = 0.59) and mental health (MH) (r = 0.78)
subscales. The correlation between EQ-5D utility values and
SF-36 subscales indicated that mental health measures; VT
(r = 0.76), SF (r = 0.71), RE (r = 0.63) and MH (r = 0.76) have
better correlation coefﬁcient than physical health measures Cor-
relation between utility and VAS scores for EQ-5D was 0.79.
CONCLUSION: Both of the instruments are measuring the QoL
and are well correlated with the HAM-D scores. However since
EQ-5D has advantages (simple, easy and fast completion) it may
be introduced even in daily practice for assessment of the QoL in
major depression patients, efﬁciently.
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OBJECTIVES: To investigate the feasibility, and patient/
psychiatrist acceptability, of sending medication reminders and
well-being questions to patients receiving quetiapine via SMS-
messages. METHODS: This study was conducted by 7 Belgian
psychiatrists in outpatients receiving quetiapine according to
local label and considered capable of using their cellular-phone
and sending SMS-messaging. Twenty-seven outpatients (11 male;
16 female, mean age: 35.3 years) were followed for 8 to12 weeks
in this psychiatrist assessed, pilot-study. Patients received SMS-
messages twice daily to remind them to take their medication and
enquire about their well-being, fun messages could be received
optionally. Patients’ response was monitored by psychiatrists via
a website, and subsequently used to assess technical feasibility.
RESULTS: Patients responded to 77% of the SMS-messages (of
which 84% total response, 13% inaccurate response, 3% late
response). Twenty patients completed the study. The mean study
duration was 9.4 weeks. Response was higher in patients who
were supported in their disease by family/friends and who
showed good motivation. More than 50% of the patients rated
the degree of support offered by SMS as valuable (to a signiﬁcant/
reasonably extent). 71% appreciated the fun messages. The 2
major beneﬁts expressed by the patients were the feeling of being
cared for (n = 11/21) and the reminding to take their medication
(n = 7/21). Most of the psychiatrists felt that the system helped
improve compliance and relationship with the patient. Psychia-
trists felt the system was valuable to 19/22 patients, 16/24
patients remained compliant with the system and 16/22 patients
felt the frequency of SMS-messages was acceptable. There was a
strong correlation between patients giving positive well-being
responses and SMS-compliance (R Pearson = 0.72, p < 0.001).
CONCLUSION: The technology was favorably accepted and
performed well. The high levels of SMS-compliance and beneﬁts
expressed by patients and psychiatrists support a larger-scale
assessment of this possibility for assistance to health care
providers and patients.
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OBJECTIVES: Cholinesterase inhibitors and the NMDA-
receptor modulator memantine present the ﬁrst-line pharmaco-
therapy for Alzheimer’s disease, the most common type of
dementia. Effective and safe therapy requires drug administration
in a particular dose regimen, at speciﬁed times, and for a speciﬁc
period of time. The present study sets out to assess the adherence
of ambulatory Alzheimer patients to antidementia drugs by
means of electronic monitoring. METHODS: Adherence was
prospectively measured using MEMS (medication event monitor-
ing system). MEMS presents a medication container with a
microprocessor in the lid that records the date and time of every
opening. The study design comprises a one month run-in phase
followed by a main phase lasting six months. Percentage of days
with correctly administered doses of medication (daily adher-
ence) in the main phase, and number of patients with at least one
monthly (30 day period) daily adherence less than 80% were
deﬁned as main outcome measures. RESULTS: Adherence was
assessed in 16 patients (11 taking a once daily medication, 5 a
twice daily). Patients were prescribed one of the following drugs:
donepezil (n = 7), galantamine (n = 4), memantine (n = 4),
rivastigmine (n = 1). Daily adherence in main phase varied
from 48.3% to 99.4% (mean = 90.5%, median = 93.6%,
SD = 12.4%). A total of 5/16 patients (31%) had at least one
monthly adherence less than 80%. CONCLUSION: In general,
the study revealed a good medication taking behaviour with one
non-adherent day out of ten on average. Nevertheless, several
individuals exhibited major discrepancies that may potentially
endanger therapeutic goals. In a next step, another cohort of
patients and their caregivers will receive a pharmaceutical care
intervention including MEMS data feedback which might help to
optimize adherence.
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